全身性エリテマトーデス(SLE)の疫学予測

DelveInsightが発行した調査報告書(DELV803016)
◆英語タイトル:Systemic Lupus Erythematosus - Epidemiology Forecast
◆商品コード:DELV803016
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2018年3月
◆ページ数:50
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2営業日以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,250 ⇒換算¥367,250見積依頼/購入/質問フォーム
Site Price(同一事業所内共有可)USD6,500 ⇒換算¥734,500見積依頼/購入/質問フォーム
Enterprise Price(同一法人内共有可)USD9,750 ⇒換算¥1,101,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

DelveInsight’s ‘Systemic Lupus Erythematosus – Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Systemic Lupus Erythematosus in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Systemic Lupus Erythematosus Epidemiology
The Systemic Lupus Erythematosus (SLE) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Systemic Lupus Erythematosus are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Systemic Lupus Erythematosus Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, sex-specific prevalent cases, Lupus Nephritis prevalent cases, diagnosed cases and treatable cases) scenario of Systemic Lupus Erythematosus (SLE) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the total number of prevalent and diagnosed population of Systemic Lupus Erythematosus (SLE) was found to be more than 5, 76,232 and 850,000 in 7MM respectively, in the year 2016.

Report Scope
• The report covers detailed overview of Systemic Lupus Erythematosus explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool of Systemic Lupus Erythematosus in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of the disease
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by gender, and Clinical Manifestation i.e., Lupus Nephritis in 7MM

Key strengths
• 10 Year Forecast of Systemic Lupus Erythematosus epidemiology
• 7MM Coverage
• Total Prevalent Cases of SLE
• Prevalent Cases according to segmentation: Gender-specific prevalence and prevalence of Clinical Manifestation i.e., Lupus Nephritis
• Diagnosed and treatable cases of SLE

Key assessments
• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

【レポートの目次】

1. Report Introduction 1
2. Systemic Lupus Erythematosus (SLE) Epidemiology Overview at a Glancye 2
2.1. Total Prevalent Cases of Systemic Lupus Erythematosus (SLE) – by Country (2017) 3
2.2. Total Market by Region of Systemic Lupus Erythematosus (SLE) (2017 & 2027) 3
3. Disease Background and Overview: Systemic Lupus Erythematosus (SLE) 10
3.1. Introduction 10
3.2. Risk Factors 10
3.3. Causes 11
3.4. Symptoms 12
3.5. Clinical Manifestations 13
3.6. Pathogenesis 17
3.7. Diagnosis 19
4. Epidemiology and Patient Population 26
4.1. Key Findings 26
4.2. Population and Forecast Parameters 27
4.3. Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM 28
4.4. Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM – By Region 29
4.5. Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM – Distribution (2017) 30
4.6. Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM – Distribution (2027) 30
5. Epidemiology of Systemic Lupus Erythematosus (SLE) 31
5.1. United States 31
5.1.1. Assumptions and Rationale 31
5.1.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in United States 33
5.1.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in United States 34
5.1.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in United States 35
5.1.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in United States 36
5.1.6. Prevalence of Lupus Nephritis (LN) in United States 37
5.2. Germany 38
5.2.1. Assumptions and Rationale 38
5.2.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) (AK) in Germany 39
5.2.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Germany 40
5.2.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in Germany 41
5.2.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in Germany 42
5.2.6. Prevalence of Lupus Nephritis (LN) in Germany 43
5.3. France 44
5.3.1. Assumptions and Rationale 44
5.3.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in France 45
5.3.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in France 46
5.3.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in France 47
5.3.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in France 48
5.3.6. Prevalence of Lupus Nephritis (LN) in France 49
5.4. Italy 50
5.4.1. Assumptions and Rationale 50
5.4.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in Italy 51
5.4.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Italy 52
5.4.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in Italy 53
5.4.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in Italy 54
5.4.6. Prevalence of Lupus Nephritis (LN) in Italy 55
5.5. Spain 56
5.5.1. Assumptions and Rationale 56
5.5.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in Spain 57
5.5.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Spain 58
5.5.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in Spain 59
5.5.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in Spain 60
5.5.6. Prevalence of Lupus Nephritis (LN) in Spain 61
5.6. United Kingdom 62
5.6.1. Assumptions and Rationale 62
5.6.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in United Kingdom 63
5.6.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in United Kingdom 64
5.6.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in United Kingdom 65
5.6.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in United Kingdom 66
5.6.6. Prevalence of Lupus Nephritis (LN) in United Kingdom 67
5.7. Japan 68
5.7.1. Assumptions and Rationale 68
5.7.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in Japan 70
5.7.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Japan 71
5.7.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in Japan 72
5.7.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in Japan 73
5.7.6. Prevalence of Lupus Nephritis (LN) in Japan 74
6. Treatment Practices 75
6.1. Treatment Goals 75
6.2. Treatment Algorithm 76
7. Unmet Needs 80
8. Appendix 125
9. Report Methodology 125
9.1. Sources Used 125
10. DelveInsight Capabilities 127
11. Disclaimer 128
12. About DelveInsight 128

Table 1: Major clinical manifestations of Systemic Lupus Erythematosus (SLE) 13
Table 2: THE 1982 REVISED CRITERIA FOR CLASSIFICATION OF SYSTEMIC LUPUS ERYTHEMATOSUS 19
Table 3: Differential Diagnosis of Systemic Lupus Erythematosus 20
Table 4: Diagnostic Criteria for Systemic Lupus Erythematosus 22
Table 5: Diagnostic Tests for Systemic Lupus Erythematosus 24
Table 6: Total Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7 MM (2016-2027) 28
Table 7: Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM (2016-2027) 29
Table 8: Prevalent Population of Systemic Lupus Erythematosus (SLE) in United States (2016-2027) 33
Table 9: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in United States (2016-2027) 34
Table 10: Treatable Population of Systemic Lupus Erythematosus (SLE) in United States (2016-2027) 35
Table 11: Sex-Specific Distribution of Systemic Lupus Erythematosus (SLE) in United States (2017) 36
Table 12: Prevalent Population of Lupus Nephritis (LN) in United States (2016-2027) 37
Table 13: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027) 39
Table 14: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027) 40
Table 15: Treatable Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027) 41
Table 16: Sex-Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Germany (2017) 42
Table 17: Prevalent Population of Lupus Nephritis (LN) in Germany (2016-2027) 43
Table 18: Prevalent Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027) 45
Table 19: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027) 46
Table 20: Treatable Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027) 47
Table 21: Sex-Specific Prevalent Population of Systemic Lupus Erythematosus (SLE) in France (2017) 48
Table 22: Prevalent Population of Lupus Nephritis (LN) in France (2016-2027) 49
Table 23: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027) 51
Table 24: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027) 52
Table 25: Treatable Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027) 53
Table 26: Sex-Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Italy (2017) 54
Table 27: Prevalent Population of Lupus Nephritis (LN) in Italy (2016-2027) 55
Table 28: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027) 57
Table 29: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027) 58
Table 30: Treatable Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027) 59
Table 31: Sex-Specific Prevalent Population of Systemic Lupus Erythematosus (SLE) in Spain (2017) 60
Table 32: Prevalent Population of Lupus Nephritis (LN) in Spain (2016-2027) 61
Table 33: Prevalent Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027) 63
Table 34: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027) 64
Table 35: Treatable Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027) 65
Table 36: Sex-Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in UK (2017) 66
Table 37: Prevalent Population of Lupus Nephritis (LN) in United Kingdom (2016-2027) 67
Table 38: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027) 70
Table 39: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027) 71
Table 40: Treatable Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027) 72
Table 41: Sex-Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Japan (2017) 73
Table 42: Prevalent Population of Lupus Nephritis (LN) in Japan (2016-2027) 74


Figure 1: Risk Factors of SLE 13
Figure 2: Pathogenesis of Systemic Lupus Erythematosus 20
Figure 3: Algorithm for diagnosis of Systemic Lupus Erythematosus 25
Figure 4: Total Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7 MM (2016-2027) 30
Figure 5: Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM (2016-2027) 31
Figure 6: Prevalent Population of Systemic Lupus Erythematosus (SLE) in US (2016-2027) 35
Figure 7: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in US (2016-2027) 36
Figure 8:Treatable Population of Systemic Lupus Erythematosus (SLE) in US (2016-2027) 37
Figure 9: Sex- Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in US (2017) 38
Figure 10: Prevalent Population of Lupus Nephritis in United States (2016-2027) 39
Figure 11: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027) 41
Figure 12: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027) 42
Figure 13:Treatable Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027) 43
Figure 14: Sex- Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Germany (2017) 44
Figure 15: Prevalent Population of Lupus Nephritis in Germany (2016-2027) 45
Figure 16: Prevalent Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027) 47
Figure 17: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027) 48
Figure 18:Treatable Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027) 49
Figure 19: Sex- Specific Prevalent Population of Systemic Lupus Erythematosus (SLE) in France (2017) 50
Figure 20: Prevalent Population of Lupus Nephritis in France (2016-2027) 51
Figure 21: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027) 53
Figure 22: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027) 54
Figure 23:Treatable Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027) 55
Figure 24: Sex- Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Italy (2017) 56
Figure 25: Prevalent Population of Lupus Nephritis in Italy (2016-2027) 57
Figure 26: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027) 59
Figure 27: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027) 60
Figure 28:Treatable Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027) 61
Figure 29: Sex- Specific Prevalent Population of Systemic Lupus Erythematosus (SLE) in Spain (2017) 62
Figure 30: Prevalent Population of Lupus Nephritis in Spain (2016-2027) 63
Figure 31: Prevalent Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027) 65
Figure 32: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027) 66
Figure 33:Treatable Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027) 67
Figure 34: Sex- Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in UK (2017) 68
Figure 35: Prevalent Population of Lupus Nephritis in United Kingdom (2016-2027) 69
Figure 36: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027) 72
Figure 37: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027) 73
Figure 38:Treatable Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027) 74
Figure 39: Sex- Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Japan (2017) 75
Figure 40: Prevalent Population of Lupus Nephritis in Japan (2016-2027) 76


【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 全身性エリテマトーデス(SLE)の疫学予測(Systemic Lupus Erythematosus - Epidemiology Forecast )]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆